Kornimate/medical-research-clean huggingface dataset:
artificial intelligence-assisted diagnosis

Conditions: Congenital Heart Disease (CHD); Structural Heart Disease

Summary: this study aims to investigate whether an ai-assisted decision support can improve the diagnosis of congenital heart diseases on chest x-ray.

congenital heart disease (chd) is a structural abnormality of the heart and/or great vessels and the frequency of chd is nearly 1% in general population. in clinical practice, chest x-ray is an important routine method for detection of chd. however, its learning curve is high. based on chest x-ray, artificial intelligence (ai) has the potential to improve the efficiency and accuracy of chd. this study aims to investigate whether an ai-assisted decision support can improve the diagnosis of congenital heart diseases on chest x-ray. this study will enroll subjects with chd, and the enrollment will be divided into two phases. phase 1: previous data of chest x-ray in patients with chd. a minimum of 3000 patients is reached. phase 2: prospective inclusion of general patients with chest x-ray. a minimum of 5000 patients is reached.

Eligibility criteria:
inclusion criteria: 1. chest x-ray of patients with asd; 2. chest x-ray of patients with vsd; 3. chest x-ray of patients with pda; 4. chest x-ray of patients with pfo; 5. chest x-ray of patients with ps; 6. chest x-ray of patients with tof/paa; 7. chest x-ray of patients with ms; 8. chest x-ray of patients with other heart diseases; exclusion criteria: 1. chd patients without surgical, interventional validation; 2. serious scoliosis; 3. pulmonary inflammation or consolidation

Keywords: artificial intelligence；congenital heart diseases；chest x-ray；diagnosis
spect-ct metabolic/morphological assessment of cemented hip protheses

Conditions: Arthropathy of Hip

Summary: single center, pilot, randomized, controlled clinical trial to assess metabolic and morphological images between two types of cemented stem prostheses in patients undergoing total hip arthroplasty surgery during a 2-year follow up period.

single center, pilot, controlled clinical trial to assess metabolic and morphological images of patients undergoing total hip arthroplasty surgery randomized to the thick layer technique (exeter hip stem model) or to the "french paradox" technique (müller straight stem model). participants will be performed a plain radiography and a spect-ct at 3, 6, 12 and 24 months of the intervention. spect-cts will be performed in addition to the usual medical care complementary imaging exams. the spect will require the administration of the 99mtechnetium-methylene diphosphonate (99mtc-mdp) radiopharmaceutical (useful to assess bone metabolism) and its combination with a ct scan (spect-ct) allows a combined metabolic and morphological study.

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years-old * both genders * patients undergoing a primary total hip arthroplasty surgery with implantation of a cemented prosthesis (exeter hip stem model or müller straight stem model) * patients with a diagnosis of hip osteoarthritis, operated by the orthopedic surgery and traumatology department at the bellvitge university hospital * patients who signed the written informed consent. exclusion criteria: * patients allergic to 99mtc-mdp radiopharmaceutical * patients with claustrophobia * patients with a background of an active septic process * patients with a postoperative septic complication * patients periprosthetic fracture or misalignment of the prosthetic component * patients who have a total hip prosthetic implanted due to a subcapital femoral fracture

Keywords: hip arthroplasty french paradox thick-layer spect metabolic changes ct scan morphological changes
epicardial adipose tissue and arterial stiffness in people living with diabetes (metab-cv-pwv)

Conditions: Diabetic Patients

Summary: the present study is a retrospective and prospective current care cohort that will allow us to evaluate the relationship between epicardial fat volume and increased arterial stiffness in a person living with diabetes.

epicardial adipose tissue is considered as the cardiac visceral fat and is associated with increased cardiovascular risk, for example in diabetes. thus, the mechanisms involved seem to be related to myocardial lipotoxicity; atherosclerosis in connection with inflammation and secretion of proinflammatory factors such as cytokines but also insulin resistance. in this context, the investigators hypothesize that epicardiac adipose tissue volume will be higher in patients with increased arterial stiffness than in those without. in this study, the investigators will then try to verify the existence of a relationship between pericardial adipose tissue volume and increased arterial stiffness in people living with diabetes. to do this, the investigators will analyze the results of measurements of pericardial fat volume, coronary calcium score, and pulse wave velocity in diabetic patients.

Eligibility criteria:
inclusion criteria: patients will be eligible for participation in the study if: * they are informed and have not objected to participating in the research. * they have type 1 or 2 diabetes. * they perform a coronary calcium score measurement by ct scan and a pulse wave velocity assessment during their routine care practice.

Keywords: diabet arterial stiffness pericardial adipose tissue
efficacy and safety of dlbs3233 in prediabetic patients

Conditions: Prediabetic

Summary: this is a 2-arm, prospective, double blind, randomized, and controlled clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of dlbs3233. it is hypothesized that dlbs3233 will delay the progress of beta-cell dysfunction as measured by the improvement of prandial (particularly the first phase) insulin secretion as well as insulin resistance in prediabetic subjects which may prevent the conversion of prediabetes into type 2 diabetes mellitus.

there will be two groups of treatment in this study who will receive dlbs3233 or placebo of dlbs3233 for 12 weeks of therapy. subjects will be provided with an education on lifestyle modification given by the assigned nutritionist. all subjects will be advised to follow such a lifestyle modification throughout the study period. all subjects will be under direct supervision of a medical doctor during the study period. all clinical and laboratory examinations to evaluate the investigational drug's efficacy, will be performed at baseline, week 8th and week 12th (end) of study treatment. blood glucose level (both fpg and 2h-pg) will be performed at baseline and at interval of 4 weeks over the 12 weeks of study treatment. safety examinations will be performed at baseline and at the end of study. occurrence of adverse event will be observed during the study.

Eligibility criteria:
inclusion criteria: * male or female subjects with age of 18-60 years * prediabetic patients (2h-pppg level of 140-199 mg/dl) * serum alt ≤ 2.5 times upper limit of normal * serum creatinine \< 1.5 times upper limit of normal * able to take oral medication exclusion criteria: * female of childbearing potential * history of diabetes mellitus * history of symptomatic coronary arterial disease, stroke, and cardiovascular events * current treatment with systemic corticosteroids or herbal (alternative) medicines * any other disease state or uncontrolled illness, which judged by the investigator, could interfere with trial participation or trial evaluation * participation in any other clinical studies within 30 days prior to screening

Keywords: prediabetic primary prevention type 2 diabetes mellitus
effects of combining different exercise modes with cpt on vascular function and sleep quality in female university students with sd

Conditions: Sleep Quality; Vascular Function

Summary: fourteen female college students with sleep disorders (sd) and fourteen with good sleep status were recruited, divided into sleep disorder group (sdg) and control group (cg). both groups underwent moderate-intensity continuous training (mict), high-intensity interval training (hiit), and sprint interval training (sit). immediately after exercise, cold pressor test (cpt) was administered, vascular indicators were measured immediately and 30 minutes later. the next day after exercise, participants completed the pittsburgh sleep quality index (psqi). each exercise mode had a washout period of at least 7 days.

both sdg and cg underwent hiit, mict, and sit interventions. after the exercise, a cpt was conducted, and vascular indicators were immediately measured at the end of the intervention. another measurement was taken 30 minutes after the intervention. the exercise was performed on a power bike, with the requirement to maintain a pedaling frequency of 60 rpm. the exercise protocols for hiit, mict, and sit were designed with equal exercise volume. the hiit protocol consisted of 4 sets of 4 minutes at 85% maximal oxygen uptake data (vo2max), interspersed with 3 minutes at 50% vo2max. the mict protocol involved continuous pedaling at 60% vo2max for 32 minutes. the sit protocol included 6 sets of 30-second all-out sprints (100% vo2max) with 4.5 minutes of recovery at 60% vo2max between each sprint. there was a minimum of 7 days between each exercise mode as a washout period. the psqi questionnaire was completed the day after each intervention upon waking up.

Eligibility criteria:
inclusion criteria: * female university students aged between 18 and 30 years old * body mass index (bmi) between 18.5\~24.0 kg/m2 * presence of sd (psqi \> 8 points) or good sleep quality (psqi ≤ 7 points) * not taking medications that affect sleep * no cardiovascular diseases * no regular exercise habits or specialized training but possessing the ability to complete the exercise program exclusion criteria: * severe organic diseases such as heart, kidney, etc * metabolic diseases such as diabetes, etc. * taking medications that affect sleep (including drugs that promote or interfere with sleep) * permanent and severe exercise dysfunction * participation in other experiments

Keywords: exercise sleep disorders cold pressor test vascular function
antibiotic-associated coagulopathy

Conditions: Infection; Blood Coagulation Disorders

Summary: over the past few decades, a good number of studies with regard to coagulopathy and increased bleeding tendency which is defined as macro- or microscopic hemorrhage, declination of hemoglobin level, thrombocytopenia, and hypoprothrombinemia potentially caused by the use of antibiotics through a variety of suggested mechanisms, including myelosuppression, immune-mediated destruction of thrombocytes and coagulation factors, and suppression of vitamin k epoxide reductase or vitamin k-dependent γ-glutamate carboxylase which may lead to inhibition of biosynthesis of coagulation factor ii, vii, ix, and x, have been reported or published. nevertheless, many of them are case-series studies or case reports with low level of evidence, and there have been no large-scale retrospective cohort studies regarding antibiotic-associated coagulopathy being published. moreover, in addition to exposure to antibiotics, there are several risk factors, including severity of illness, hepatic or renal function, nutrition status, comorbidities such as cancer and hematologic disease, surgery or other invasive procedure, concomitant use of anticoagulants, nsaids, and salicylates, and age, which may exert influence on the function of the coagulation system as well. therefore, the study aims to clarify the association between the use of antibiotics and the increase of bleeding tendency or the development of bleeding event and to identify possible risk factors of the increase of bleeding tendency or the development of bleeding event in patients receiving antibiotic treatment through the application of nested case-control design and the usage of both the national health insurance research database (nhird) and medical records in national taiwan university hospital during the time period from january, 1995 to december, 2013.


Eligibility criteria:
inclusion criteria: * patients aged older than 20 years old * using antibiotics for more than 48 hours in the emergency department exclusion criteria: * shift of antibiotic prescription in the er * patients with hemorrhage -related diagnoses * non-temporally consecutive referral from the er to the ward
obesity and cardiovascular diseases, cross-sectional study in saudi arabia

Conditions: Obesity and Cardiovascular Risk

Summary: the purpose of this research study is to collect information on participants body weight, blood sugar levels, heart related diseases and lifestyle. the collected information will help estimate the prevalence of participants disease. this study will take about 6 months. however, participants involvement in the study will not extend beyond their routine visit and will thus require a maximum of 1 day. if participants choose to take part, they will be asked to give information about their health in routine clinical visit. participants will be asked to complete a questionnaire about their lifestyle. participants will complete this questionnaire during their normally scheduled visit with their doctor. participants will continue their normal way of life and will not get any medication other than those prescribed to them by their doctor. participants will have no direct benefit from participation in this study and there are no risks involved. participants decide voluntarily whether they want to participate in this study or not. participants' decision will not affect their medical care and they do not have to justify their decision. participants are free to leave the study at any time and without giving reasons. this does not affect their current or future treatment. the data collected up to that point are still being evaluated. there is no additional cost to participants for being in this study.


Eligibility criteria:
inclusion criteria: 1. signed consent obtained before any study related activities (study related activities are any procedure-related to recording of data according to the protocol). 2. diagnosed with obesity (bmi higher than or equal to 30 for all ethnic groups except asian; bmi higher than or equal to 27.5 for patients of asian ethnicity). 3. diagnosed with t2d for patients in cohort 2. 4. male or female, aged between 18 and 75 years at the time of signing informed consent exclusion criteria: 1. participation in an interventional clinical trial during the study period. 2. diagnosed with t2d for patients in cohort 1. 3. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
liposomal bupivacaine versus standard bupivacaine in the adductor canal for total knee arthroplasty

Conditions: Pain

Summary: study will evaluate the effect of liposomal bupivacaine versus standard bupivacaine on physical therapy measures and pain scores as well as opiate consumption.

total knee arthroplasty (tka) can be associated with a large amount of postoperative pain. this pain can oftentimes be severe enough to limit participation in physical therapy and ultimately delay discharge resulting in increased cost. several strategies have been developed in an effort to decrease postoperative pain following tka while maintaining lower extremity strength and maximizing participation in physical therapy. recently, adductor canal blockade has gained popularity as it is reported to provide analgesia to the anterior knee without resulting in significant quadriceps muscle weakness. one downside of single shot peripheral blockade is the duration of analgesia can oftentimes be short lived. the advent of depot local anesthetics has made this an attractive option, especially in busy practices where placing peri-neural catheters may not be practical or cost effective. this study aims to carefully evaluate this relationship using a physical therapy evaluation method that relies on both motor strength and pain control. in addition, we hope to carefully evaluate motor strength using a novel method of strength measurement in an effort to further evaluate the impact of depot local anesthetic injection into the adductor canal on physical therapy and analgesia.

Eligibility criteria:
inclusion criteria: 1. the subject is scheduled for elective unilateral tka; 2. the subject is ≥ 18 years and ≤ 80 years; 3. the subject's weight is between 65-130 kg; 4. the subject's primary anesthesia care team has planned for a neuraxial anesthetic (i.e. spinal, epidural or combined-spinal epidural); 5. the patient agrees to receive an adductor canal block; 6. american society of anesthesiologists class 1-3. exclusion criteria: 1. subject is \ 80 years of age; 2. subject is non-english speaking; 3. subject is known or believed to be pregnant; 4. subject is a prisoner; 5. subject has impaired decision-making capacity per discretion of the investigator; 6. symptomatic untreated gastroesophageal reflux or otherwise at risk for perioperative aspiration; 7. any condition for which the primary anesthesia care team deems neuraxial anesthesia inappropriate; 8. significant pre-existing neuropathy on the operative limb; 9. significant renal, cardiac or hepatic disease per discretion of the investigator; 10. american society of anesthesiologists class 4-5; 11. known hypersensitivity and/or allergies to local anesthetics; 12. chronic opioid use (daily or almost daily use of opioids for \> 3 months).

Keywords: 10 meter walk test opioid consumption
hypofractionated loco-regional adjuvant radiation therapy of breast cancer combined with a simultaneous integrated boost

Conditions: Lymphedema; Fibrosis

Summary: the purpose of the study is to investigate the difference in late radiation morbidity between hypofractionated and normofractionated loco-regional breast irradiation irrespective of mastectomy or lumpectomy. in patients who a candidates for a boost, the boost will be provided as a simultaneous integrated boost.

the randomization is between 50 gy / 25 fractions and 40 gy/15 fractions, 5 fractions weekly. in patients treated with boost 2 dose levels are accepted: 16 gy/8 fractions and 10 gy/5 fractions. these boost treatments will be provided as simultaneous integrated boost, where the overall treatment time in general is shortened 5 days. thus the dose levels for boost patients are: 63 gy / 51.52 gy / 28 fractions, 57 gy / 50 gy / 25 fractions, 52.2 gy / 42.3 gy / 18 fractions, and 45.75 gy / 40 gy / 15 fractions. the primary endpoint is arm lymphedema 3 years after radiation therapy, but other late radiation morbidities will also be evaluated along with recurrence and sites of recurrence. follow up of morbidity will continue for 10 years. the hypothesis is that women operated for early breast cancer with indication for loco-regional radiation therapy can be offered moderately hypofractionated therapy without developing more late radiation induced morbidity compared to normofractionated radiation therapy.

Eligibility criteria:
inclusion criteria: operated for early node-positive breast cancer with indication for loco-regional breast radiotherapy exclusion criteria: previous radiotherapy to chest wall, pregnant/lactating, comorbidity which may hinder 10 years follow up

Keywords: radiation induced morbidity, recurrence
effects of farinelli's breathing exercise in copd patients

Conditions: COPD Patients

Summary: this study was to investigate the effect of farinelli's breathing exercise on pulmonary function, respiratory muscle strength, aerobic capacity, impact of copd questionnaires, cytokines, and oxidative stress in patients with chronic obstructive pulmonary disease (copd).

sixteen patients with copd (gold i) with mild and moderate (gold ii) severity aged 51 - 80 years old who visited at the outpatient examination room, phramongkutklao hospital divided into 2 groups; diaphragmatic breathing group (db; n=8) and farinelli's breathing group (fb; n=8). participants in each group were administered to complete breathing exercise 5 times per week for 8 weeks. physiological data and pulmonary function (fvc, fev1, pef, fev1/fvc, fef25-75%, mvv, vc, tv, irv, erv and ic), respiratory muscle strength (mip and mep), aerobic capacity (6-mwd and vo2max), impact of copd questionnaire (mmrc and cat), cytokine (tnf-α and il-6), and oxidative stress (mda) were analyzed during pre- and post-test.

Eligibility criteria:
inclusion criteria: * patients with copd who treated in phramongkutklao hospital * have a history of smoking * fev1 predicted after bronchodilator more than 50% * no change in medication in 4 weeks * no history of acute exacerbation in 4 weeks * no history of cardiac disease. exclusion criteria: * recurrent of acute exacerbation * cannot participate at least 80% of training program (≤ 32 sessions of 40 sessions) * unwilling to continue practicing.

Keywords: farinelli's breathing exercise copd pulmonary function respiratory muscle strength aerobic capacity cytokine copd symptoms
efficacy study for the symptomatic treatment of seasonal allergic rhinitis

Conditions: Seasonal Allergic Rhinitis

Summary: the objective of the study is to evaluate the efficacy and tolerability of bilastine 20 mg, compared to cetirizine and placebo for the treatment of seasonal allergic rhinitis.

in this pivotal, multicentre, international, randomized, double-blind, placebo and active-comparator controlled, parallel study, 683 patients with sar will be enrolled. patients will be required to be 12-70 years old, have sar for ≥2 years, a positive skin test, total nasal and non-nasal score (tss) ≥36 (out of 72) during run-in, and a composite instantaneous nasal symptom score ≥6 (out of 12) the morning before randomization. the primary efficacy endpoint will be the auc of reflective tss from baseline to day 14.

Eligibility criteria:
inclusion criteria: * patients of either sex between 12 and 70 years of age. * patients with documented clinical history of sar, for at least 2 years prior to the study inclusion. * positive skin prick test for at least one of the seasonal allergen specific of the geographical area. * a previous positive prick test, or a positive ige test (rast) may also be accepted for inclusion, if performed within 12 months prior to the inclusion. exclusion criteria: * patients who have non-allergic rhinitis (vasomotor, infectious, drug-induced, etc.). * negative skin prick test (as defined in point 6.1.1.). * patients with nasal polyps or a significant deviation of the nasal septum as judged by the investigator as well as nasal intervention in the previous 6 months. any other nasal illness that can interfere with the aim of the study. * patients who have acute or chronic sinusitis as judged by the investigator. * patients who have received anti-allergy immunotherapy in the previous two years or are still receiving this kind of therapy. * patients who are taking or have taken specified medications prior to randomisation in the study and have not complied with the specified washout period

Keywords: rhinitis allergic seasonal hay fever pollen allergy pollinosis rhinoconjunctivitis